Common-Size Balance Sheet: Assets
Paying users area
Try for free
Abbott Laboratories pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Balance Sheet: Liabilities and Stockholders’ Equity
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Capital Asset Pricing Model (CAPM)
- Return on Equity (ROE) since 2005
- Price to Earnings (P/E) since 2005
The data is hidden behind: . Unhide it.
Get 1-month access to Abbott Laboratories for $24.99, or
get full access to the entire website for at least 3 months from $62.19.
This is a one-time payment. There is no automatic renewal.
We accept:
Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).
Balance sheet item | Description | The company |
---|---|---|
Current assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events. | Abbott Laboratories current assets as a percentage of total assets increased from 2021 to 2022 but then decreased significantly from 2022 to 2023. |
Net property and equipment | Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. | Abbott Laboratories net property and equipment as a percentage of total assets increased from 2021 to 2022 and from 2022 to 2023. |
Long-term assets | Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer. | Abbott Laboratories long-term assets as a percentage of total assets decreased from 2021 to 2022 but then increased from 2022 to 2023 exceeding 2021 level. |